Revolution's pan-RAS drug advances to Phase III for pancreatic cancer

Revolution Medicines recently announced that its pan-RAS inhibitor, RMC-6236, will proceed to Phase III clinical trials in the treatment of pancreatic cancer, following promising results from its Phase I study. The biotech company shared data demonstrating tumour reductions between 20% and 27% in patients with pancreatic ductal adenocarcinoma (PDAC). This latest data release builds on findings presented in October and includes outcomes from 127 PDAC patients who were administered RMC-6236 doses ranging from 160mg to 300mg.

Among the patients with KRAS G12X mutations who had undergone one or more previous treatments, the overall response rates (ORRs) were observed to be 20% at the 14-week analysis and increased to 27% at the 20-week mark. For a broader category of patients with RAS mutations, which includes G12X, G13X, or Q61X PDAC, the ORRs were reported at 21% and 26% for the same timeframes, respectively.

By comparison, Revolution Medicines highlighted that the benchmark average ORR from published reports stands at approximately 9%. This illustrates a significant improvement in response rates with RMC-6236.

In terms of disease progression, the median progression-free survival (PFS) for second-line KRAS G12X patients was reported to be 8.1 months. For those receiving the treatment in a third-line-plus setting, the median PFS was 4.2 months. Standard chemotherapy regimens typically show a PFS of 2 to 3.5 months. For the broader group of RAS mutant patients, the median PFS reached 7.6 months.

These encouraging results indicate a potential new treatment option for those suffering from pancreatic cancer, particularly those with specific genetic mutations. Revolution Medicines is optimistic about the future phases of RMC-6236's development and its potential impact on pancreatic cancer treatment options. More details are anticipated as the Phase III trials commence and further data becomes available.